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Abstract
Background: Aerosolized delivery of antibiotics is hindered by poor penetration within distal and plugged
airways. Antibacterial perfluorocarbon ventilation (APV) is a proposed solution in which the lungs are partially
or totally filled with perfluorocarbon (PFC) containing emulsified antibiotics. The purpose of this study was to
evaluate emulsion stability and rheological, antibacterial, and pharmacokinetic characteristics.
Methods: This study examined emulsion aqueous droplet diameter and number density over 24 hr and emulsion
and neat PFC viscosity and surface tension. Additionally, Pseudomonas aeruginosa biofilm growth was
measured after 2-hr exposure to emulsion with variable aqueous volume percentages (0.25, 1, and 2.5%) and
aqueous tobramycin concentrations (Ca¼0.4, 4, and 40mg/mL). Lastly, the time course of serum and pul-
monary tobramycin concentrations was evaluated following APV and conventional aerosolized delivery of
tobramycin in rats.
Results: The initial aqueous droplet diameter averaged 1.9– 0.2lm with little change over time. Initial aqueous
droplet number density averaged 3.5– 1.7· 109 droplets/mL with a significant ( p< 0.01) decrease over time.
Emulsion and PFC viscosity were not significantly different, averaging 1.22– 0.03· 10–3 Pa$sec. The surface
tensions of PFC and emulsion were 15.0 – 0.1· 10–3 and 14.6– 0.6· 10–3 N/m, respectively, and the aqueous
interfacial tensions were 46.7– 0.3· 10–3 and 26.9– 11.0· 10–3 N/m ( p< 0.01), respectively. Biofilm growth
decreased markedly with increasing Ca and, to a lesser extent, aqueous volume percentage. Tobramycin
delivered via APV yielded 2.5 and 10 times larger pulmonary concentrations at 1 and 4 hr post delivery,
respectively, and significantly ( p< 0.05) lower serum concentrations compared with aerosolized delivery.
Conclusions: The emulsion is bactericidal, retains the rheology necessary for pulmonary delivery, is suffi-
ciently stable for this application, and results in increased pulmonary retention of the antibiotic.
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Introduction
Bacterial Biofilms are a key pathologic feature ofchronic airway infections and an important cause of
morbidity.(1–3) Limited diffusion from the epithelial lining
fluid into the biofilm mass and enhanced resistance make
biofilm-based infections refractory to the concentration of
antibiotics typically achieved with systemic administra-
tion.(4) Inhaled aerosolized antibiotics have shown the ability
to achieve higher intrapulmonary antibiotic concentrations
while limiting systemic toxicity and, as a result, have estab-
lished an important role in treatment.(4–6) However, there are
still many shortcomings associated with inhaled antibiotics in
the treatment of bacterial respiratory infections, making
aerosolized delivery less than ideal. High sputum production
by the infected host and poor ventilation in lung regions with
the largest infectious burden can cause ineffective delivery to
these areas.(6,7) In addition, the narrow range of aerosolized
particle sizes resulting in effective penetration of the lower
airways presents further difficulties.(7,8) The nonuniform in-
trapulmonary distribution of delivered antibiotics resulting
from these challenges can hamper infection clearance as well
as promote the development of antibiotic resistance.(9) For
these reasons, a modified method of antibiotic delivery to the
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lungs resulting in more spatially uniform distribution and
increased pulmonary residence time could significantly im-
prove the treatment of chronic respiratory infections.(6,10)
Antibacterial perfluorocarbon ventilation (APV) is thus
proposed as an adjunct to traditional systemic or inhaled an-
tibiotic therapy. During APV, the lung is filled with a liquid
perfluorocarbon (PFC) containing emulsified antibiotic (i.e.,
water-in-PFC) and ventilated for a few hours. This can be
done by either partially filling the lung and then ventilating
with gas (partial APV) or fully filling the lung and ventilating
with liquid PFC (total APV). Although APV could be used in
a variety of respiratory infection cases, it would be best suited
for patients already on a ventilator due to the need for the
patient to be intubated during the therapy. Respiratory bac-
terial infections in cystic fibrosis, chronic obstructive pulmo-
nary disease, and bronchiectasis are common and often
exacerbate the disease state, thus often requiring the patient to
be mechanically ventilated. Such patient groups could greatly
benefit from APV with very little added procedures or dis-
comfort. If successful in this setting, the technique might also
be attempted to treat persistent infections in these same pa-
tients. Here, prevention of recurrent exacerbations might off-
set the undesirable necessity of sedating the patient for APV.
In theory, APV could improve antibiotic therapy in sev-
eral ways. First, antibiotic is delivered directly to the source
of infection, yielding higher concentrations in the lung and
lower systemic concentrations. Second, PFCs have anti-
inflammatory properties that may promote lung healing and
improve mucociliary clearance.(11–15) Lastly, tidal PFC flow
during ventilation can actively detach infected mucus from
the airway walls due to fluid shear, reduced surface tension,
and buoyancy. The mucus can then be transported from the
lungs via suction (partial APV) or the ventilating emulsion
(total APV). Although this article is confined to the delivery
of antibiotics, PFC-based drug delivery in general may offer
a treatment advantage for any condition in which improved
drug penetration is desired.
Ventilation with PFC liquids has been previously used as a
means of respiratory support. In this application, it has proven
able to remove mucus and inflammatory exudates,(16–18) to
distribute uniformly within injured lungs, and to provide re-
spiratory support in animal models(19–22) and in humans with
acute respiratory distress syndrome.(17,23–25) PFC-based an-
tibiotic delivery has been previously explored, primarily
through the use of solid particle suspensions.(26–28) Although
ventilation with such suspensions has shown some promise, it
has failed to demonstrate treatment benefit over systemic
antibiotic delivery in conjunction with liquid ventilation.(27)
In the current study, we examined the stability and rheolog-
ical, anti-biofilm, and pharmacokinetic characteristics of an
emulsion consisting of aqueous tobramycin in a PFC vehicle.
To be effective in its intended application, the emulsion must
(i) be effective against typical airway biofilm pathogens such
as Pseudomonas aeruginosa, (ii) be stable over the intended
2-hr duration of treatment, and (iii) maintain surface tensions,
aqueous interfacial tensions, and viscosity similar to those of
neat PFC. Low surface tension and aqueous interfacial ten-
sion are necessary for the liquid to penetrate otherwise
plugged airways and aid in mucus detachment.(29) The vis-
cosity of PFCs has significant effects on our ability to ade-
quately ventilate the lungs (30) and the shear stress–induced
disruption of infected mucus lining the airways.
Materials and Methods
Tobramycin-PFC emulsion formulation
A perfluorinated polyether-polyethylene glycol (PEG)
block copolymer surfactant (Fig. 1A), was synthesized as
previously described.(31) The emulsion was prepared by
first dissolving 6mg of Krytox 157 FSL (poly[oxy[trifluoro
(trifluoromethyl)-1,2-ethanediyl]], a-(1-carboxy-1,2,2,2-tetra
fluoroethyl)-x-[tetrafluoro(trifluoromethyl)ethoxy]-, CAS
no. 51798-33-5; DuPont, Wilmington, DE) and 6mg of
Krytox-PEG copolymer in 0.6mL of PFC liquid. The
PFC used in all experiments was perfluorocycloether/per-
fluorooctane (FC-770; 3M Inc., St. Paul, MN). FC-770 has
been used in previously published studies on partial liquid
ventilation.(32–34) For eventual clinical translation, a PFC
with a higher level of purity and larger amount of docu-
mented in vivo safety data would be used. Next, 125 lL of
0.4, 4, or 40mg/mL tobramycin (Abraxis Pharmaceutical
Products, Schaumburg, IL) in sterile saline was added. The
mixture was emulsified via sonication (model 450, 20 kHz,
3.2mm diameter; Branson, Danbury, CT) at 200 W/cm2 for
60 sec in continuous mode. PFC was then added to the
emulsion to a final volume of 5mL and was sonicated for an
additional 10 sec to disperse the aqueous droplets in the PFC
phase. Additional PFC was then added to the emulsion to
create the varying aqueous volume percentages examined.
Particle size and number
The number and size distribution of aqueous droplets in an
emulsion containing 2.5% aqueous volume were acquired
via photomicrography using a hemacytometer (Brightline,
Hausser Scientific, Horsham, PA). Images were digitally
acquired using Spot Advanced Software (Diagnostic Instru-
ments Inc., Sterling Heights, MI) and processed in MA-
TLAB (The MathWorks Inc., Natick, MA) to determine the
number of droplets per volume and their size distribution. To
determine emulsion stability, analysis was repeated 1, 2, and
24 hr after preparation. Five different optical fields of view
(FOV), each containing a minimum of 500 droplets per
FOV, were analyzed to determine the droplet number density
and size distribution at each time point. This manual droplet
counting/sizing method has been used with similarly sized
emulsions and shown to produce results not statistically
different from those obtained using a Coulter counter.(31,35)
Emulsion viscosity
The dynamic viscosities of neat PFC and emulsions with
aqueous volume percentages ranging from 0.3 to 2.5% were
measured using a cone and plate rheometer (AR 1000; TA
Instruments, New Castle, DE) at 37C. Samples were interro-
gated over a range of shear rates from 20 to 500 sec–1, cap-
turing a range of values estimated to be achieved at the airway
epithelium during total liquid ventilation. Three repeated
measurements were taken for each set of conditions examined.
Emulsion surface tension and aqueous
interfacial tension
The surface tension and aqueous-emulsion interfacial
tension of an emulsion containing 2.5% aqueous volume, as
well as the corresponding properties of neat PFC, were
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measured using a DuNouy ring tensiometer with a platinum-
iridium ring (6 cm circumference; Interfacial Tensiometer;
CSC Scientific Company Inc., Fairfax, VA). Immediately
after emulsion preparation, 10–15mL of emulsion or neat
PFC was placed in a petri dish and allowed to reach room
temperature (22–25C) before being used for measure-
ments. For aqueous-emulsion or aqueous-PFC interfacial
tension measurements, 10mL of deionized, filtered water
was introduced on top of the emulsion or neat PFC. Three
repeated measurements were taken for each set of condi-
tions examined.
Anti-biofilm activity
Pseudomonas aeruginosa strain ATCC 27853 was gen-
erously provided by David McLeod (Gilead Laboratories,
Foster City, CA). This strain is a cystic fibrosis–derived
strain selected for its biofilm-forming capacity. Biofilms
were grown on solid-phase transfer pin lids as described
elsewhere(36) and as summarized in Figure 2A. Bacteria
were first grown in tryptic soy broth (TSB) with 1% glucose
at 37C on a gyratory shaker. A solution of approximately
108 colony forming units (CFU) per milliliter of mid-log
growth P. aeruginosa in TSB with 1% glucose was then
placed into wells of a 96-well plate (150lL/well). A solid-
phase transfer pin lid (Nunc-TSP 445497; Nunc, Rochester,
NY) was then placed such that pins were immersed in the
bacterial broth. Trays were incubated for 18 hr at 37C
without shaking. Pin-adherent biofilms were then exposed to
the emulsions, neat PFC, aqueous antibiotics, or growth
medium by transferring the lid to a new 96-well plate. All
emulsions in Table 1 were examined. After 2 hr of exposure,
biofilms were centrifuged for 20min at 840 g into fresh
growth medium (TSB with 1% glucose). Because centrifu-
gally released biofilm material could not be reliably sepa-
rated into individual cells to perform CFU counting,
bacterial viability from recovered biofilms was quantified as
the change in broth turbidity over 6 hr. Luria-Bertani agar
cultures were used to confirm complete biofilm killing in
cases where no change in broth turbidity occurred over 6 hr
of observation. Sixteen wells were used for each type of
exposure, resulting in 16 repeated measurements for each
set of conditions examined.
Pharmacokinetic characterization
Specific pathogen-free, male Sprague Dawley rats [n = 20,
weight 401– 14 (SD) g; Charles River Laboratories, Wil-
mington, MA] were divided into the following groups:
partial APV treatment (n = 10) and aerosolized treatment
(n = 10). All rats were initially anesthetized with a mixture
of ketamine hydrochloride [50mg/kg, intraperitoneal (IP);
Hospira Inc., Lake Forest, IL] and xylazine hydrochloride
(5mg/kg, IP; Lloyd Laboratories, Shenandoah, IA). Rats
receiving aerosolized treatment were then placed in a prone
position and orally intubated with a 16-G angiocatheter.
FIG. 1. (A) Perfluorinated polyether-poly-
ethylene glycol (PEG) block copolymer sur-
factant (n= 13 and m = 75) used to stabilize
water:PFC interface. (B) Size distribution of
aqueous droplets in reverse PFC emulsion ini-
tially and 24 hr after formulation. (C) Number
density of aqueous droplets over time. (D)
Viscosity over differing shear rates for neat
PFC and emulsions with different aqueous
volume percentages. (E) Surface tensions and
aqueous interfacial tensions of neat PFC and
emulsion.
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Aerosolized delivery was accomplished via a Microsprayer
Aerosolizer (Model IA-1B; Penn-Century, Wyndmoor, PA).
Prior to intubation, the length of the angiocatheter was
trimmed to ensure that the Microsprayer nozzle was suffi-
ciently exposed when the Microsprayer was fully inserted
into the angiocatheter. Following intubation with the trim-
med angiocatheter, the Microsprayer was fully inserted into
the angiocatheter and tobramycin (15mg/kg in 250lL of
sterile saline) was delivered intratracheally. Following de-
livery, rats were extubated and allowed to recover under
supplemental oxygen provided via a nose cone. For rats
receiving partial APV, intravenous (IV) access was acquired
via the lateral tail vein following initial anesthesia. Sedation
was maintained with a constant IV infusion of ketamine
hydrochloride (0.6mg/kg/min). Heart rate and arterial oxy-
gen saturation were monitored via a pulse oximeter (VetOx
Plus 4800; Heska, Loveland, CO). Rats were orally in-
tubated with a 16-G angiocatheter and connected to a ven-
tilator (Model 683; Harvard Apparatus, Holliston, MA).
Ventilation was carried out with a tidal volume of 9mL/kg,
a respiratory rate of 50–80 breaths/min, a positive end-
expiratory pressure of 3 cm H2O, and a fraction of inspired
oxygen (FiO2) of 1. Respiratory rate was adjusted to
maintain peak inspiratory pressures less than 30 cm H2O.
Preoxygenated emulsion (15mL/kg, 2.5% aqueous by vol-
ume, 40mg/mL aqueous tobramycin concentration) was
instilled via a port connected to the angiocatheter, resulting
in a delivered dose of 15mg/kg tobramycin. The emulsion
was prepared no more than 20min before use and was in-
stilled slowly over a period of less than 3min without in-
terrupting gas ventilation. Gas ventilation was continued for
60min following delivery of the emulsion, after which the
rats were either euthanized or allowed to recover under
supplemental oxygen.
Rats were euthanized with pentobarbital sodium (175mg/kg,
IP, Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI) and
the lungs removed aseptically at either 1 hr (n = 5 for each
treatment group) or 4 hr (n = 5 for each treatment group)
following the delivery of tobramycin. In the 4-hr groups,
blood samples were also drawn via the lateral tail vein at
30, 60, 120, and 240min following the delivery of tobra-
mycin. Serum tobramycin concentration measurements were
FIG. 2. (A) Sequence of steps in biofilm exposure experiment. (B) Scanning electron micrograph (10,000· ) of typical
biofilm. (C) Six-hour biofilm growth after 2-hr exposure to emulsions with different aqueous volume percentages and
different aqueous particle tobramycin concentrations. (D) Six-hour biofilm growth after 2-hr exposure to TSB alone,
tobramycin in TSB (100lg/mL), or neat PFC.
Table 1. Emulsion Formulations
Aqueous
volume
percent
Krytox and
Krytox
copolymer
concentration
(mg/mL
emulsion)
Aqueous
tobramycin
concentration
(mg/mL H2O)
Total
tobramycin
concentration
(lg/mL
emulsion)
0.25 0.12 0.4 1
1.0 0.48 0.4 4
2.5 1.2 0.4 10
0.25 0.12 4 10
1.0 0.48 4 40
2.5 1.2 4 100
0.25 0.12 40 100
1.0 0.48 40 400
2.5 1.2 40 1,000
Formulations of all emulsions were examined for anti-biofilm
activity.
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performed via an immunoassay by the Department of Pa-
thology within the University of Michigan Hospital. Lung
tissue was homogenized with 10mL of sterile saline, and the
presence of active tobramycin in the homogenate was
measured via a microbiological assay as previously de-
scribed(37) with the following exception: seeded agar plates
were prepared by inoculation of the surface of Luria-Bertani
agar plates with 750lL of diluted culture. The lower limit of
detection using these methods was 5 lg/mL. Any result
below this limit was assigned a value of 5lg/mL as a
conservative estimate (see Results). In addition to the to-
bramycin-treated samples, lung tissue from untreated rats
and rats receiving an emulsion containing only sterile saline
in the aqueous phase was examined as a negative control.
Statistical analysis
SPSS (IBM Corporation, Armonk, NY) was used to
perform one- or two-way ANOVA and post-hoc t tests on
comparisons of interest. The Tukey-Kramer method was
applied to differentiate significant differences between
groups. Repeated-measures ANOVA was used to determine
the effect of treatment mode on serum tobramycin concen-
tration with time after delivery used as the independent,
repeated variable. Differences were deemed significant for
p < 0.01 unless otherwise specified. All subsequent reported
values are given as means– SD unless otherwise specified.
Results
Emulsion physical characteristics
The aqueous droplet diameter, aqueous droplet number
density, emulsion viscosity, emulsion surface tension, and
aqueous-emulsion interfacial tension data are shown in
Figure 1B–E. Emulsions containing 2.5% aqueous volume
had an initial mean aqueous droplet diameter of 1.9 – 0.2 lm
and droplet number density of 3.5 – 1.7 · 109 droplets/mL.
Aqueous droplet diameter was shown to be stable, with no
significant change between 0 and 24 hr. Aqueous droplet
number density was shown to significantly change over
time, exhibiting a nearly half-log decrease over 24 hr. The
emulsions and neat PFC exhibited Newtonian behavior with
constant viscosities over the range of shear rates examined
(20–500 sec–1). No significant differences in viscosity were
seen between neat PFC and emulsions. Over all of the shear
rates tested, the ranges of average viscosities were 1.22–
1.32 · 10–3, 1.21–1.34 · 10–3, and 1.26–1.37· 10–3 Pa$sec
for emulsions with 2.5, 0.3, and 0% (neat PFC) aqueous
volume, respectively. Lastly, the mean surface tensions of
neat PFC and emulsion (2.5% aqueous by volume) were
15.0 – 0.1 · 10–3 and 14.6 – 0.6 · 10–3 N/m, respectively.
The mean aqueous-PFC and aqueous-emulsion interfacial
tensions were 46.7 – 0.3 · 10–3 and 26.9 – 11.0· 10–3 N/m
( p < 0.01) for neat PFC and emulsion (2.5% aqueous by
volume), respectively.
Anti-biofilm activity
A typical biofilm recovered from an immersed peg is
shown in Figure 2B. As shown in Figure 2C and D, to-
bramycin delivered via emulsion was capable of significantly
limiting or altogether preventing growth in biofilm-derived
P. aeruginosa after a 2-hr exposure. Intraparticle aqueous
tobramycin concentrations of at least 4mg/mL were neces-
sary to reduce the proliferation of biofilm-derived bacteria
following exposure, and bactericidal effects were achieved
only with aqueous tobramycin concentrations of 40mg/mL
at the highest aqueous volume percentage (2.5%). Under
these conditions, the total well concentration of tobramycin
that the biofilm was exposed to was 1,000lg/mL, and eight
of 16 replicates had no growth on follow-up culture at 24 hr.
It is important to note that a mean inhibitory concentration
cannot be determined in a traditional way with this emulsion,
as bacterial growth is a function of both the overall antibiotic
concentration and that within an individual droplet.
Pharmacokinetic characterization
Lung tissue from an untreated rat and a rat receiving
ventilation with an emulsion containing only saline in the
aqueous phase produced no distinguishable zones of inhibi-
tion. As shown in Figure 3A, tobramycin delivered via partial
APV resulted in significantly higher concentrations in the
lung tissue at both 1 and 4 hr post delivery relative to aero-
solized treatment. Mean lung tissue homogenate tobramycin
concentrations at 1 hr post delivery were 197– 36 and
FIG. 3. (A) Effective tobramycin concentration of lung tissue homogenate (lung tissue + sterile saline) at 1 and 4 hr
following tobramycin delivery via partial APV (white) and aerosolized delivery (shaded). (B) Tobramycin concentration of
serum at 30, 60, 120, and 240min following tobramycin delivery via partial APV (solid line) and aerosolized delivery
(dotted line). Errors bars represent standard deviations.
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78– 18lg/mL for partial APV and aerosolized treatment,
respectively. Mean lung tissue homogenate tobramycin con-
centrations at 4 hr post delivery were 82– 14 and 8– 4lg/mL
for partial APV and aerosolized treatment, respectively.
Furthermore, three of five measurements in the aerosolized
group at 4 hr post delivery resulted in concentrations below
the lower limit of detection (5lg/mL). A two-way ANOVA
showed a statistically significant effect of treatment mode
(partial APV or aerosolized delivery; p< 0.01) and time post
delivery (1 or 4 hr; p< 0.01) on lung tissue homogenate to-
bramycin concentrations. Serum tobramycin concentrations
from rats receiving tobramycin delivered via partial APV or
aerosolized treatment are shown in Figure 3B. A repeated-
measures ANOVA showed that tobramycin delivery via
partial APV produced significantly ( p< 0.05) lower serum
concentrations relative to aerosolized delivery. Maximum
measured serum tobramycin concentrations for partial APV
and aerosolized treatments were 9.1– 1.5 and 14.4– 4.0
lg/mL and occurred at 60 and 30min, respectively.
Discussion
In the current work, we demonstrated the feasibility of
formulating a PFC emulsion containing tobramycin and its
effectiveness as an antibiotic delivery vehicle. In order for
this emulsion to be effective, it must be relatively stable
over the likely application duration ( < 2 hr), preserve PFC’s
viscosity and low interfacial tensions that allow for effective
ventilation, and be bactericidal. Our emulsion has met these
conditions. The sonication process for generating the
emulsion is straightforward and could readily be performed
just prior to administration, similar to the activation of ul-
trasound contrast agents [e.g., Definity (Lantheus Medical
Imaging) or Optison (GE Healthcare)] or preparation of
drug-laden emulsions used in chemoembolization.(38)
Aqueous droplet size was sufficiently stable over a period
of 24 hr, whereas a significant decrease in aqueous droplet
number density was observed over the same period. Multi-
ple destabilization phenomena, including Ostwald ripening
and coalescence, could be responsible for these observa-
tions. Coalescence of aqueous droplets within the emulsion
would directly increase mean droplet size as well as de-
crease droplet number density. During Ostwald ripening,
larger droplets will tend to grow in size at the expense of
smaller droplets, which decrease in size. Because the optical
methods used to size the droplets cannot account for
nanometer-sized droplets, it is possible that Ostwald ripen-
ing caused some small, but initially countable droplets to
become undetectable at later time points. This would cause
even a small increase in mean droplet size to correlate to a
large decrease in the measurable droplet number density.
The viscosity of the emulsion compared with that of neat
PFC was not substantially different. This is not surprising
given the low volumetric fraction of aqueous phase in the
emulsion (0.3–2.5%). This range of aqueous volume per-
centages examined was determined by considering the tar-
geted mass of drug to be delivered relative to the lung fill
volumes used in these trials (functional residual capacity).
The surface tension of the emulsion did not significantly
differ from that of neat PFC, whereas the aqueous-emulsion
interfacial tension was shown to be considerably less than
the aqueous-PFC interfacial tension. This behavior is likely
due to the addition of surfactant when forming the emulsion.
Due to their hydrophilic and fluorophilic moieties, the sur-
factants likely accumulate at the emulsion–aqueous inter-
face, causing a decrease in the interfacial tension. These
results show that the emulsion exhibits the low surface
tension of PFCs that allows them to penetrate small,
branching airways and alveoli during liquid ventilation and
an even lower aqueous interfacial tension (relative to neat
PFC) that should enhance mucus removal.(39,40) First, low
aqueous-PFC interfacial tension allows the PFC to more
effectively penetrate airways that are partially or fully
plugged with mucus. Second, it reduces the adhesivity of
the mucus during liquid ventilation, resulting in mucus de-
tachment at lower flow rates and shear stresses.(29,39)
As expected, the tobramycin concentration needed within
the aqueous phase to achieve bacterial killing against bio-
films was substantially higher than the measured plank-
tonic mean bactericidal concentration against this strain (25
lg/mL; data not shown). The reasons are likely twofold.
First, antibiotic activity against biofilms is known to be re-
duced. Second, the physical means of antibiotic delivery
from the droplets to the biofilm is not yet understood and
may be reducing antibiotic effectiveness.
It is worth noting that although the aqueous phase
concentrations of tobramycin are quite high, the total dose
administered to a patient using this technology is similar to
currently used doses. If the highest concentration and
aqueous volume percentage in our study were to be used
clinically (40mg/mL aqueous phase tobramycin concen-
tration, 2.5% aqueous by volume), a 70-kg patient under-
going partial APV with a 15mL/kg dose of the emulsion
(the dose used in previous clinical trials of partial
liquid ventilation) would receive approximately 1 g of
tobramycin instilled into the lung. However, at the com-
pletion of therapy, a significant amount of the emulsion
would be drained from the lung. Conservatively, estimat-
ing that 10mL/kg is left behind, the delivered dose would
be 700mg, only slightly larger than the currently re-
commended 600mg daily inhaled dose.(41) However, the
fraction of the administered dose actually delivered to the
lungs may be higher during APV than aerosolized delivery
due to aerosolized drug loss via exhaled drug as well as
deposition in the oropharyngeal region and delivery de-
vice. It should be noted that the in vivo efficacy of different
emulsion formulations has not yet been determined. The
ideal aqueous volume percentage, aqueous phase to-
bramycin concentration, and fill volumes are all likely to
change based on their in vivo efficacy.
Based on these results, delivery of the same tobramycin
dose via emulsion may lead to lower toxicity than aerosol-
ized delivery. Pulmonary retention of the delivered to-
bramycin was significantly greater for partial APV than
aerosolized delivery (2.5 times larger at 1 hr post delivery
and 10 times larger at 4 hr post delivery). As a result, peak
serum concentrations resulting from partial APV were
smaller and occurred at a later time point relative to aero-
solized treatment, suggesting delayed absorption of drug
into the pulmonary circulation. Clearance of tobramycin
from the systemic circulation after approximately 60min
post delivery appears to be similar between the two modes
of treatment. The difference in pharmacokinetics observed
between the two routes of administration could also be due
PERFLUOROCARBON EMULSIFIED ANTIBIOTICS 397
in part to a difference in the mass of drug reaching the lungs.
Aerosolized delivery in this study was performed with the
Microsprayer nozzle positioned within the rat trachea. Al-
though this technique likely results in much greater lung
deposition than shown with clinical devices in humans, it
may still result in some drug deposition in the trachea,
thereby potentially reducing the fraction of drug reaching
the lungs.
The physical means by which antibiotic is transferred
from aqueous droplets within the emulsion to the aqueous
surfaces of the lung (epithelial lining fluid or biofilm mass)
is not yet understood and warrants further investigation. The
bactericidal effects resulting from biofilm exposure to
emulsions as well as the presence of tobramycin in the
systemic circulation following APV treatment indicate that
the antibiotic is available and delivery is achieved. A better
understanding of this process would allow for easier opti-
mization of the emulsion and therapy in order to achieve
maximum treatment benefit.
Lastly, the long-term safety of the fluorinated surfactants
used (Krytox 157 FSL and Krytox-PEG copolymer) was not
assessed in this work. Although multiple in vitro studies
have shown biocompatibility of nonionic Krytox-PEG
copolymer surfactants with mammalian cells,(42–44) the
biocompatibility in an application such as APV has not been
assessed. Accordingly, future work should examine the
long-term, in vivo biocompatibility of these surfactants
when used during APV, as well as the possible use of other
suitable surfactants. In this study, excess surfactant was
used to ensure stability. Future work will examine the de-
gree to which this concentration can be reduced while still
retaining emulsion stability and bactericidal effectiveness.
This includes (i) finding the minimum concentration of
surfactant needed to stabilize specific aqueous volume
percentages and (ii) reducing total surfactant using more
concentrated aqueous tobramycin at a smaller aqueous
volume percentage.
In conclusion, the tobramycin-PFC reverse-phase emul-
sion exhibits a stable droplet size over a period of 24 hr,
maintains the same viscosity as neat PFC, retains a low
surface tension, creates an even lower aqueous interfacial
tension than that of neat PFC, and is capable of significantly
lowering bacterial growth. In addition, delivery of to-
bramycin via partial APV results in enhanced pulmonary
retention as well as delayed absorption into the systemic
circulation relative to aerosolized delivery. Therefore, this
emulsion may provide a novel treatment for lower respira-
tory infections during APV through a two-pronged ap-
proach: biofilm and mucus removal and simultaneous
antibiotic delivery. Future investigations are needed to
evaluate this treatment in animal models of lower respira-
tory infections.
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